Press

Hemplucid Becomes First Startup to Provide Psychedelic Therapy as Employee Healthcare Benefit

Jul 28 • 3 min read

HempLucid, a leading provider of plant-based wellness supplements, is the first startup to offer medically supervised Ketamine-Assisted Therapy (KAP) as an employee benefit. Ketamine is a general anesthetic, first used on the battlefields of Vietnam because it did not slow the heartrate like other anesthetics. Today, ketamine is used by first responders to calm people trying to…

U.S. Patent Grant to Strengthen Small Pharma’s DMT Patent Strategy With Injectable Formulation

Jul 28 • 3 min read

Small Pharma Inc. (TSXV: DMT | OTCQB: DMTTF), a biotechnology company focused on short-acting psychedelic-assisted therapies for mental health conditions, today announces that it has received Issue Notification from the United States Patent and Trademark Office that its patent application no. 17/459,284 will be granted on August 9, 2022 in the United States under patent no….

Silo Pharma Announces Positive Results from its Topically Administered Formulation of Ketamine

Jul 28 • 2 min read

Silo Pharma, Inc . (OTCQB: SILO), a development-stage biopharmaceutical company today announced that its topically administered Ketamine reached a positive end point in an animal study. Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate…

Filament Health Announces Participation in Project Solace

Jul 28 • 2 min read

Filament Health Corp. (OTCQB: FLHLF | NEO: FH | FSE: 7QS), a clinical‐stage natural psychedelic drug development company, today announced its participation in Project Solace, the world’s largest medical psilocybin access and data project. Project Solace is led by TheraPsil in collaboration with Drug Science. Filament has enrolled in the project as a Health Canada-licensed producer of psilocybin. “We…

COMPASS Pathways launches phase II clinical trial of psilocybin therapy in anorexia nervosa

Jul 28 • 4 min read

COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it has launched a multi-centre, double-blind randomised controlled phase II clinical trial investigating the efficacy of COMP360 psilocybin, administered with psychological support, in people with anorexia nervosa. The phase II clinical trial…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420